BIAF jumps as bioAffinity highlights expanded CyPath Lung use case

bioAffinity Technologies (BIAF) is up 46.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied primarily to a September 1 company announcement that broadened the commercial narrative around CyPath Lung by positioning the test for surveillance of lung cancer survivors, not just initial risk assessment. This could also be because traders are reacting more aggressively after the recent reverse split reduced the share count, which can magnify volatility in small-cap names.

Details:

The company said it is advancing CyPath Lung for monitoring patients who have completed curative-intent lung cancer treatment, adding a new potential use case for the product.

The announcement framed lung cancer survivorship as a sizable market and emphasized that the test may complement imaging when new pulmonary nodules appear after treatment.

Recent operating updates showed strong commercial momentum, including a 216% year-over-year increase in second-quarter 2026 CyPath Lung test volume and growth in ordering physician offices.

A 1-for-15 reverse stock split became effective on August 24, 2026, leaving roughly 592,373 shares outstanding immediately afterward; that lower share count could be amplifying the stock's reaction to fresh news.

Sources:

bioAffinity Technologies, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive BIAF Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$BIAF Hedge Fund Activity

We have seen 13 institutional investors add shares of $BIAF stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

SABBY MANAGEMENT, LLC added 365,647 shares (+inf%) to their portfolio in Q2 2026, for an estimated $296,905
BLACKROCK, INC. added 98,777 shares (+inf%) to their portfolio in Q2 2026, for an estimated $80,206
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 26,870 shares (+inf%) to their portfolio in Q2 2026, for an estimated $21,818
JANE STREET GROUP, LLC added 26,784 shares (+inf%) to their portfolio in Q2 2026, for an estimated $21,748
SCHONFELD STRATEGIC ADVISORS LLC removed 24,413 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $19,823
HRT FINANCIAL LP added 20,834 shares (+inf%) to their portfolio in Q2 2026, for an estimated $16,917
CITADEL ADVISORS LLC removed 11,631 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $44,546

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.